Treating acute ischemic strokes involves a precarious clinical balance: physicians must dissolve arterial clots to save brain tissue without triggering catastrophic intracranial hemorrhaging. To address the severe bleeding risks associated with traditional thrombolytic medications, Basking Biosciences has developed an innovative paired-drug system featuring an experimental clot-busting therapy (BB-031) and a rapid-acting molecular “off switch” (BB-025), as reported on Inside Precision Medicine.
The clinical need for a safer stroke treatment is acute. Dr. Shahid Nimjee, a neurosurgeon and Basking’s chief scientific officer, highlights the severe morbidity tied to current drugs like tenecteplase, noting that he has frequently “gone into patients and operated on their brains trying to stop TNK-induced bleeding.” To circumvent this, Nimjee spent two decades developing BB-031, an RNA aptamer designed to selectively inhibit von Willebrand factor (vWF)—a protein essential for clot growth and stabilization. Because BB-031 is constructed from a specific single-stranded RNA sequence, researchers were able to engineer BB-025, a complementary oligonucleotide. When administered, BB-025 binds to the therapeutic aptamer via Watson-Crick base pairing, disrupting its three-dimensional structure and instantly neutralizing its ability to bind to vWF.
Recent Phase I trials involving 60 healthy volunteers demonstrated the remarkable efficacy of this reversal mechanism. Basking announced that BB-025 safely and completely reversed the biological activity of BB-031 within five minutes, successfully restoring vWF and platelet function. The drug was well tolerated with no severe adverse events. Basking CEO Dr. Julia C. Owens noted that while preclinical models were promising, the sheer speed and durability of the human trials “exceeded our expectations.” The company views the naturally short half-life of RNA aptamers not as a limitation, but as an asset for stroke care, where the ideal intervention is a high-dose drug that breaks up the clot and quickly clears the system, backed by a reversal agent if bleeding occurs.
This enhanced safety profile and layer of pharmacological control could vastly expand stroke treatment eligibility. Currently, 80% to 85% of ischemic stroke patients do not qualify for existing treatments like intravenous thrombolytics or mechanical thrombectomies. Owens projects that this reversible therapy has the potential to safely treat “as much as half of those patients who don’t receive treatment today.”
While Phase I verified the safety and mechanics of the reversal agent in healthy individuals, the system’s clinical viability is now being tested in an international Phase IIb trial. This double-blind, placebo-controlled study will evaluate BB-031 in 180 actual stroke patients, determining if this novel drug-and-antidote approach can effectively dissolve clots and improve neurological outcomes without the devastating hemorrhagic side effects of its predecessors.
